

GALNT14

Subjects: Genetics & Heredity

Contributor: Chau-Ting Yeh

Members in the polypeptide N-acetylgalactosaminyltransferase (GALNT) family function as the initiating enzymes to catalyze mucin-type O-glycosylation of proteins, of which dysregulated expression can alter cancer cell behaviors such as de novo occurrence, proliferation, migration, metastasis and drug resistance. One of its members, GALNT14, is aberrantly expressed in multiple cancers and involved in a variety of biological functions. Moreover, the single nucleotide polymorphisms (SNPs) of *GALNT14*-rs9679162 has been shown to predict the therapeutic outcomes in patients with hepatocellular carcinoma as well as several other different types of gastrointestinal cancers.

Keywords: polypeptide N-acetylgalactosaminyltransferase ; single nucleotide polymorphism ; biomarker ; cancer

1. Introduction

Glycosylation, an enzymatic process that attaches glycans to proteins or other organic molecules, is essential for multicellular life. Among several types of glycosylation, addition of a sugar to the oxygen atom of amino acid residues (O-glycosylation) occurs on thousands of secreted and cell surface proteins, altering their structures, functionalities and subcellular distributions ^{[1][2][3][4]}. O-glycans are built by adding sugar molecules to protein sequentially. The members in N-acetylgalactosaminyltransferase (GALNT) family are enzymes that initiate O-glycosylation by addition of an N-Acetylgalactosamine (GalNAc) to a Serine or Threonine residue of mucin-type protein ^[5]. This process plays a pivotal role in the synthesis of Thomsen-nouvelle (Tn) antigens, which are well-characterized tumor-associated molecules ^[6]. The GALNT families contain 20 members, from GALNT1 to 14 and from GANLTL1 to L6 ^[5]. In cancer, the altered O-glycosylation by GALNTs may affect a variety of biological processes, including tumor progression, proliferation and migration ^[7].

GALNT14 was firstly cloned and identified from gastric cancer cell line MKN45 in 2003 ^[8]. The *GALNT14* gene is located at chromosome 2p23.1, spanning over 228kb and containing at least 17 exons (Figure 1A). It has been found in many human tissues and highly expressed in skin and kidney ^[8].

The GALNT14 protein is a 552-amino acid, type-II membrane protein that consists of a N-terminal cytoplasmic domain, followed by a transmembrane domain, a stem region, and a catalytic domain (Figure 1B) ^[6]. The catalytic domain includes a glycosyltransferase 1 motif, a Gal/GalNAc transferase motif, and a ricin-like lectin motif, which are commonly observed in the GALNT family proteins ^[9]. The glycosyltransferase 1 motif appears to be responsible for Mn²⁺ coordination and binding both GalNAc and ribose of the sugar nucleotide donor ^[10]. The Gal/GalNAc transferase motif contains the catalytic general base of the β 1,4-galactosyltransferase family. The ricin-like lectin motif contains three homologous repeats (α , β and γ) and may function to modulate and improve the catalytic efficiency of Gal/GalNAc transferase ^[5].

The functions of GALNT14 in various cancers have been studied, including alteration of apoptotic signaling ^[11], change of tissue invasiveness, and modulation of migration properties ^{[12][13][14][15]}. GALNT14 expression also regulates multi-drug resistance in breast cancer cells ^[16]. Clinically, GALNT14 level serves as a prognostic marker for neuroblastoma ^[17] and non-small cell lung cancer (NSCLC) ^[15]. It has been proposed as a predictive marker for Apo2L/TRAIL-based anticancer therapy ^[11]. Finally, a single nucleotide polymorphism (SNP) in *GALNT14* gene, rs9679162, has been identified as a prognostic marker in several gastrointestinal cancers. This review summarizes our current knowledge of GALNT14 functions in various tumors, so as to provide insights into its predictive values in the therapeutic outcomes of cancers.




Figure 1. The structure of *GALNT14* gene, including the location of rs9679162 (A), and the common functional domains of GALNT proteins (B). The *GALNT14* gene is located on chromosome 2 and includes at least 17 exons. The rs9679162 is located between exon 3 and 4 (A). The members in GALNT family possess several common functional domains (B). The N-terminal cytoplasmic domain contains 4 to 22 amino acids. The transmembrane domain contains 15 to 25 amino acids. The catalytic region contains more than 450 amino acids, which can be divided into three parts: a glycosyltransferase 1 motif, a Gal/GalNAc-T motif and a ricin like motif.

2. Discovery of a *GALNT14* SNP, capable of predicting therapeutic outcomes for hepatocellular carcinoma (HCC) patients receiving systemic chemotherapy, transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), and sorafenib treatment.

The predictive value of *GALNT14*-rs9679162 SNP was firstly discovered in patients with advanced HCC receiving systemic chemotherapy. Subsequently, this SNP was found to associate with several other anti-HCC treatments, including TACE, HAIC and sorafenib. These results were summarized in Table 1.

2.1. *GALNT14*-rs9679162 SNP discovery and its association with HCC under chemotherapy

The predictive value of *GALNT14*-rs9679162 SNP in cancer was first discovered in a study attempting to identify germline SNP markers capable of predicting the treatment responses of advanced HCC patients receiving chemotherapy using 5-fluorouracil, mitoxantrone and cisplatin (FMP) [18]. Two steps of experiments were conducted in this study. Firstly, a genome-wide association study (GWAS) was performed in a cohort of 16 patients who either suffered from rapid disease progression ($n = 9$), or had partial ($n = 5$) or complete ($n = 2$) treatment responses, retrospectively. Among 16 SNPs on chromosomes 2, 6, 15 and X achieving allelic Chi-square test p -values smaller than 0.0001, *GALNT14*-rs9679162 had the lowest p -value ($p = 0.000017$) by using the kernel-based association test. Secondly, validation of SNP rs9679162 in association with therapeutic responses was performed in an independent cohort of 41 patients prospectively. In this validation cohort, significant association was found again between rs9679162 and the therapeutic responses ($p = 0.006326$). A follow-up survival analysis demonstrated that patients with "TT" genotype had better progressive-free survival (PFS) in both retrospective and prospective cohorts ($p=0.00041$ and 0.01485 , respectively) than "non-TT" ("GT" + "GG") genotypes. However, the overall survival (OS) was only significantly different in the retrospective cohort ($p = 0.00622$) but not in the prospective cohort. This study demonstrated firstly that *GALNT14*-rs9679162 genotypes is potentially associated with the responses of the first course of FMP chemotherapy in patients with advanced HCC and could serve as a predictor marker in HCC.

To confirm the predictive value of *GALNT14*-rs9679162, a prospective study was conducted in advanced HCC patients receiving a less toxic, split-dose FMP protocol [19]. 107 patients with advanced HCC stage (Barcelona Clinical Liver Cancer stage C with either main portal vein thrombosis and/or distal metastasis) were enrolled and treated by split-dose FMP therapy. Of these patients, 28 (26.2%) were "TT" and 79 (73.8%) were "non-TT" genotype. The patients with "TT" genotype, when compared to "non-TT", had better prognosis, including longer OS (6.8 vs. 3.9 months, $p < 0.001$) and PFS (3.9 vs. 2.1 months $p < 0.001$), and better response rate (28.6% vs. 10.1%, $p = 0.029$) and disease control rate (35.7% vs. 15.2%, $p = 0.030$). Further multivariate analysis confirmed that rs9679162 genotype was an independent predictor for OS ($p = 0.002$). Categorical analysis showed a subgroup of patients with "TT" genotype, tumor size $< 10\text{cm}$ and neutrophils $< 74\%$ had the best outcome (median OS 25.5 months, therapeutic response rate 47.1%). This prospective study confirmed that *GALNT14*-rs9679162 SNP is an effective predictor for therapeutic outcome in advanced HCC patients receiving split-dose FMP chemotherapy.

To evaluate whether combination of the SNP and other clinical parameters together with on-treatment side effects serves as an effective predictor for favorable outcome, 118 advanced HCC patients receiving split-dose FMP were retrospectively enrolled for the study [20]. Results showed that pretreatment α -fetoprotein (AFP) $\leq 2,800$ ng/mL (median level), *GALNT14* "TT" genotype, on-treatment leukopenia and absence of vomiting were independent predictors for favorable PFS ($p =$

0.001, 0.035, 0.008 and 0.009, respectively) and OS ($p = 0.028$, 0.006, 0.027 and 0.013, respectively). A total of 30 patients (25.4%) with both AFP $\leq 2,800$ ng/mL and GALNT14 "TT" genotype exhibited longer median PFS and OS (3.11 vs. 2.11 months, $p = 0.014$; and 5.75 vs. 3.93 months, $p = 0.001$, respectively), and 9 patients (7.6%) with all four favorable factors exhibited the longest median PFS and OS (10.64 vs. 2.07 months, $p = 0.002$; and 25.50 vs. 4.50 months, $p < 0.001$, respectively). This results suggested that lower AFP level in combination with GALNT14 "TT" genotype could serve as favorable pre-therapeutic predictors for advanced HCC patients receiving FMP chemotherapy.

The distribution of different GALNT14 genotypes in HCC has been demonstrated to be related to HCC etiologies and ethnicities [21]. The "TT" genotype was lower in percentage among patients with virus-originated HCC compared with those with non-viral HCC (22.57% vs 47.06%, $p = 0.023$). The proportion of the "TT" genotype in Chinese population ranged from 24.18% to 30.15% in different cohorts. It was significantly higher in Japanese and African population (42.11-54.55%, $p < 0.0001$), but significantly lower in an Italian cohort (7.84%, $p = 0.004$).

2.2. GALNT14-rs9679162 SNP association with HCC patients receiving TACE

TACE is currently the standard treatment in HCC patients with Barcelona Clinic Liver Cancer stage B. A cohort of 327 HCC patients treated by TACE was enrolled to investigate the prognosis predictive value of GALNT14-rs9679162 genotype [22]. Again, the "TT" genotype was associated with better prognosis, including shorter time-to-response (HR = 2.362, $p < 0.001$), time-to-complete response (HR = 1.947, $p = 0.004$) and longer PFS ($p < 0.001$), when compared with the "non-TT" genotype. In patients with albumin < 3.5 g/dL, the "TT" genotype was associated with longer OS ($p = 0.027$). This study showed that GALNT14 genotypes were also significantly associated with clinical outcomes of HCC patients receiving TACE.

2.3. The prediction value of combination of GALNT14-rs9679162 and other SNPs in advanced HCC receiving chemotherapy

The GALNT14-rs9679162 has been demonstrated to be capable of predicting chemotherapy responses in advanced HCC [18]. However, the GWAS also identified several other candidate SNP markers, including rs6025211, rs715171 (x-linked), LOC105369482-rs1955024 and WWOX-rs13338697. The prognostic value of these candidate markers were evaluated in an independent cohort of 116 advanced HCC patients receiving split-dose FMP chemotherapy [23]. It was shown that "TT" genotype of GALNT14 remained an effective predictor for favorable time-to-tumor progression (TTP) and OS ($p = 0.012$ and 0.002). Moreover, WWOX-rs13338697 "CT" genotype was associated with unfavorable TTP ($p = 0.031$) and rs6025211"CT" genotype was associated with unfavorable OS ($p = 0.014$). When these three SNPs were combined, patients with GALNT14-rs9679162 "TT"/WWOX-rs13338697 "non-CT" genotypes achieved the most favorable treatment outcomes ($n = 19$; median TTP, median OS and response rate were 3.9 months, 6.8 months and 4/19 [21.1%], respectively); whereas patients with GALNT14-rs9679162 "non-TT"/rs6025211 "CT" genotypes associated with the most unfavorable treatment outcomes ($n = 40$; median TTP, median OS and response rate were 1.9 months, 3.5 months and 1/40 [2.5%], respectively). The remaining patients had an intermediate clinical outcome. This study suggests that pretreatment genotyping of these SNPs helps to decide whether these patients should receive chemotherapy or other treatments.

2.4. A GALNT14 -rs9679162 genotype-guided therapeutic strategy for advanced HCC

Although targeted agents are recommended as the first-line treatment for advanced HCC, it could not significantly prolong survival in certain advanced HCC patients with distal metastasis. On the other hand, systemic chemotherapy or hepatic arterial infusion chemotherapy (HAIC) could achieve complete response in a small proportion of patients. In order to identify the subgroups of patients with the best outcome in advanced HCC patients receiving either chemotherapy, HAIC or targeted agents, previously identified SNP predictors (GALNT14-rs9679162, WWOX-rs13338697, and rs6025211) have been tested in a real-world cohort of 237 advanced HCC patients (171 receiving systemic FMP chemotherapy followed by various anticancer treatments including sorafenib; 66 receiving HAIC) [24]. The results showed that patients with all three SNPs with favorable chemotherapy outcome (GALNT14-rs9679162 "TT", WWOX-rs13338697 "non-CT" and rs6025211"non-CT") had the best complete response rate and median OS (35.3%, 17.8 vs. 5.3 months, $p = 0.024$), compared with remaining patients. When the three favorable SNP markers were combined with two clinical criteria (tumor diameter < 8 cm, neutrophil $< 80\%$), the complete response rate to chemotherapy reached to 60%. Subsequent sorafenib for chemotherapy non-responders was associated with longer OS ($p < 0.01$). Surprisingly, GALNT14 "GG" genotype was associated with longer OS ($p < 0.001$, median OS > 10.5 months) in HAIC treated patients.

To evaluate the predictive role of GALNT14-rs9679162 in patients receiving sorafenib treatment, a cohort of 81 HCC patients who was treated by sorafenib as the first-line therapy was studied [24]. The results showed that "TT" genotype was not associated with OS when all patients were included. However, it was found that "TT" genotype was associated with a longer OS ($p = 0.027$) and "GG" genotype was associated with a shorter OS ($p = 0.006$) in patients with positive anti-hepatitis C virus antibody. In patients with positive hepatitis B virus surface antigen, no significant association was found between the genotypes and prognosis ($p > 0.05$ for all comparisons).

Table 1. GALNT14 SNPs in different HCC stages and treatments.

HCC stage and treatment	Case number	Favorable Genotype (% of total patient)	Prognostic value	Reference
Advanced HCC receiving FMP C/T	16 patients for SNP discovery (retrospective cohort) 41 patients for confirmation (prospective cohort)	"TT" (37.5% in retrospective cohort; 43.9% in prospective cohort)	1. In retrospective cohort, longer PFS ($p = 0.00041$) and OS ($p = 0.0062$) 2. In prospective cohort, longer PFS in prospective cohort ($p = 0.01485$)	[18]
Advanced HCC receiving split-dose FMP C/T	107 patients (prospective cohort)	"TT" (26.2%)	1. Favorable OS (HR = 0.385, $p = 0.002$) 2. Favorable one-year survival rate (32.1% vs. 11.4%, $p = 0.018$) 3. Favorable PFS (HR = 0.431, $p = 0.001$) 4. Favorable CT response (28.6% vs. 10.1%, $p = 0.029$) 5. Favorable disease control rate (35.7% vs. 15.2%, $p = 0.030$)	[19]
Advanced HCC receiving split-dose FMP C/T	118 patients (retrospective cohort)	"TT" (25.4%)	1. Combination of AFP ≤ 2800 ng/mL, longer PFS (3.11 vs. 2.11 months, $p = 0.014$); longer OS (5.75 vs. 3.93 months, $p = 0.001$) 2. Combination of AFP ≤ 2800 ng/mL, leukopenia, absence of vomiting, longest median PFS (10.64 vs. 2.07 months, $p = 0.002$); longest OS (25.5 vs. 4.5 months, $p < 0.001$)	[20]

Advanced HCC receiving TACE	327 patients (retrospective cohort)	"TT" (29.1%)	<ol style="list-style-type: none"> 1. Shorter time-to-response (HR = 2.362, $p < 0.001$) 2. Shorter time-to-complete response (HR = 1.947, $p = 0.004$) 3. Longer PFS ($p < 0.001$) 4. In patients with albumin $< 3.5\text{g/dL}$, longer OS ($p = 0.027$) 	[22]
Advanced HCC receiving split-dose FMP C/T	171 patients (retrospective cohort)	GALNT14 "TT", WWOX-rs13338697 "non-CT" rs6025211"non-CT" (9.9%)	<ol style="list-style-type: none"> 1. Favorable CR rate (35.3%); 2. Longer OS ($p = 0.024$) 3. Combined with tumor diameter $< 8\text{cm}$ and neutrophil $< 80\%$, best CR rate (60%) 4. For chemotherapy non-responder, sorafenib has longer OS ($p < 0.01$) 	[24]
Advanced HCC receiving HAIC	66 patients (retrospective cohort)	"GG" (16.7%)	<ol style="list-style-type: none"> 1. Longer OS ($p < 0.001$) 2. Median OS > 10.5 months 	[24]
Advanced HCC receiving sorafenib as first-line therapy	81 patients (retrospective cohort)	"TT" in patients with positive anti-HCV	<ol style="list-style-type: none"> 1. Longer OS ($p = 0.027$) 	[24]

Abbreviations: AFP, α -fetoprotein; C/T, chemotherapy; HR, hazard ratio; OS, overall survival; PFS, progressive free survival; FMP, 5-fluorouracil, mitoxantrone, cisplatin; SNP, single nucleotide polymorphism; TACE, transcatheter arterial chemoembolization; GALNT14, N-acetylgalactosaminyltransferase14; HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma

3. GALNT14-rs9679162 SNP association with different GI cancers

The predictive value of GALNT14-rs9679162 SNP has been studied in various gastrointestinal (GI) cancers, including esophageal squamous cell carcinoma, gastric signet ring cell carcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma and cholangiocarcinoma (Table 2).

3.1. Esophageal squamous cell carcinoma

Concurrent chemoradiotherapy (CCRT) is the most common treatment for patients with locally advanced, unresected esophageal squamous cell carcinoma (ESCC) to prolong patient survival [25][26]. However, CCRT has a high-toxicity profile which restricts its clinical use. In order to select suitable patient group for CCRT, GALNT14-rs9679162 SNP has been examined as a therapeutic response predictor in ESCC [27]. A cohort of 108 patients with ESCC receiving CCRT was recruited. Among these patients, the GALNT14-rs9679162 "TT", "TG" and "GG" genotypes were 28 (25.9%), 51 (47.2%) and 29 (26.9%) respectively. While the genotypes were not associated with the OS, the "GG" genotype was associated with a lower rate of CCRT response (24.1% vs 50.6%, $p = 0.014$). Further multivariate Cox-proportional hazard model analysis showed that the "GG" genotype was associated with a longer time to complete/partial response (HR = 0.385, $p = 0.022$). Since the presence of a complete/partial response to CCRT was critical for advanced ESCC patients to achieve better outcome, the "GG" genotype can be used as a unfavorable predictor for CCRT in advanced CCRT.

3.2. Gastric signet ring cell carcinoma

Gastric signet ring cell carcinoma (SRCC) is one type of gastric cancer carrying a poorer prognosis compared with other types of gastric cancer [28]. However, the prognostic factors for gastric SRCC itself have seldom been delineated. To investigate whether GALNT14-rs9679162 SNP can be used as a prognostic marker in gastric SRCC, a cohort of 347 patients with gastric SRCC receiving surgical resection was recruited for the study [29]. The "TT", "TG" and "GG" genotypes of these patients were 23.34%, 59.65% and 17% respectively. The results showed that "TT" genotype was independently associated with unfavorable OS (HR = 1.550, $p = 0.048$) in SRCC with advanced stage (TNM stage IIB to IV). The subgroup analysis further revealed that the "TT" genotype was associated with unfavorable OS in SRCCs harboring more aggressive phenotypes such as node status > 0 (HR = 1.808, $p = 0.0013$), lymphatic invasion (HR = 1.587, $p = 0.021$), vascular invasion (HR = 3.389, $p = 0.0076$) and perineural invasion (HR = 1.604, $p = 0.0161$). It suggested that gastric SRCC could be stratified into different prognostic subgroups by the combination of clinicopathological factors and GALNT14 genotype. The poorest prognosis subgroup included patients having aggressive phenotype together with the GALNT14 "TT" genotype.

3.3. Colorectal adenocarcinoma

Adjuvant oxaliplatin-based chemotherapy has been suggested as a standard treatment for patients with stage III colorectal adenocarcinoma following surgical resection. Although the adjuvant chemotherapy could reduce around 30% of disease recurrence and 22% to 32% of mortality, not all patients benefit from the adjuvant therapy [30][31][32]. Therefore, the predictive role of GALNT14-rs9679162 SNP has been investigated in this group of patients [33]. A cohort of 300 patients with stage III colorectal adenocarcinoma receiving curative resection followed by oxaliplatin-based chemotherapy was retrospectively recruited. Of these patients, 18% patients had "TT" genotype and harbored an unfavorable OS (HR = 5.406, $p = 0.019$). Subgroup analysis further showed that the "TT" genotype was associated with unfavorable OS in the following subgroups: age ≥ 65 years, male, left side CRC, N2 stage, carcinoembryonic antigen > 5 ng/mL, and mucinous histology ($p = 0.012, 0.011, 0.009, 0.025, 0.013$, and 0.007 , respectively). This study concluded that "TT" genotype is an unfavorable prognostic marker in stage III colorectal adenocarcinoma receiving oxaliplatin-based adjuvant chemotherapy.

3.4. Pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive cancers with poor prognosis due to advanced presentation when diagnosed and limited therapeutic options. The lack of validated predictive markers further complicates this situation [34]. Again, the predictive value of GALNT14-rs9679162 SNP genotype was examined in PDA patients receiving surgical resection [35]. A cohort of 103 patients with PDA patients was enrolled for analysis. The GALNT14 genotype analysis revealed that 19.4%, 60.2% and 20.4% of patients had the "TT", "TG" and "GG" genotypes, respectively. Patients with the "GG" genotype had a longer mean OS time compared with that of the "non-GG" genotype (37.1 vs 16.1 months, $p = 0.005$). Further univariate followed by multivariate Cox proportional hazard analysis identified the "GG" genotype, negative resection margin, and locoregional disease as independent predictors for favorable OS ($p = 0.003, p = 0.037, p = 0.021$, respectively). The study suggested that "GG" genotype could serve as a favorable prognostic marker in patients with resected PDA.

3.5. Cholangiocarcinoma

Cholangiocarcinoma emerges from dysregulated proliferation of cholangiocytes, and is notorious for its poor prognosis and response to chemotherapy [36]. The association between the prognosis of patients with resected cholangiocarcinoma and the GALNT14-rs9679162 SNP genotype was examined [37]. A cohort of patients with cholangiocarcinoma ($n = 112$) were retrospectively recruited. Of these patients, 31.3, 49.1 and 19.6% had "TT", "TG" and "GG" genotypes, respectively. The "TT" genotype was associated with unfavorable OS in univariate analysis (HR = 2.282, $p = 0.023$). Furthermore, two tumor characteristics, perineural and vascular invasion, were independently associated with unfavorable OS ($p = 0.001$ and $p = 0.002$, respectively). In a multivariate linear analysis, the "TT" genotypes were independently associated with two known predictors of unfavorable prognosis, perineural invasion ($p = 0.035$) and lymph node metastasis ($p = 0.005$). This study concluded that the "TT" genotype was associated with perineural invasion and lymph node metastasis, as well as unfavorable OS in patients with resected cholangiocarcinoma.

Table 2. GALNT14-rs9679162 SNP in different GI cancers.

Type of GI cancers	Case number and treatment	Unfavorable		Reference
		Genotype (% of total patient)	Prognostic value	
Esophageal squamous cell carcinoma	108 patients with advanced esophageal squamous cell carcinoma with CCRT	"GG" (26.1%)	1. Lower rate of CCRT response (24.1% vs. 50.6%, $p = 0.014$) 2. Longer time to complete/partial response (HR 0.385, $p = 0.022$)	[27]
Gastric signet ring cell carcinoma	347 patients with gastric signet ring cell carcinoma receiving surgical resection	"TT" (23.3%)	1. In advaced stage (IIB to IV) group, unfavorable OS (HR = 1.550, $p = 0.048$) 2. In N > 0 subgroup, unfavorable OS (HR 1.808, $p = 0.0013$) 3. In lymphatic invasion subgroup, unfavorable OS (HR 1.587, $p = 0.0021$) 4. In vascular invasion subgroup, unfavorable OS (HR 3.389, $p = 0.0076$) 5. In perineural invasion subgroup, unfavorable OS (HR 1.604, $p = 0.0161$) 1. Unfavorable OS (HR = 5.406, $p = 0.019$) 2. In age ≤ 65 y subgroup, unfavorable OS (HR = 5.051, $p = 0.024$) 3. In male subgroup, unfavorable OS (HR = 7.337, $p = 0.030$)	[29]
Colorectal adenocarcinoma	300 patients with stage III colorectal cancer with Oxaliplatin based adjuvant CT	"TT" (18.1%)	4. In left side colorectal cancer group, unfavorable OS (HR = 7.857, $p = 0.026$) 5. In N2 stage subgroup, unfavorable OS (HR = 6.017, $p = 0.049$) 6. In CEA > 5ng/mL subgroup, unfavorable OS (HR = 11.295, $p = 0.049$) 7. In mucinous histology subgroup, unfavorable OS (HR = 13.296, $p = 0.037$)	[33]

Pancreatic ductal adenocarcinoma	103 patients with pancreatic adenocarcinoma receiving surgical resection	"Non-GG (TG+TT)" (80.6%)	1. Lower mean OS time (16.1 vs. 37.1 months, $p = 0.005$) 2. Unfavorable OS (HR = 3.663, $p = 0.003$)	[35]
Cholangiocarcinoma	112 patients with cholangiocarcinoma receiving surgical resection	"TT" (31.3%)	1. Unfavorable OS (HR = 2.282, $p = 0.023$) 2. Associated with perineural invasion ($p = 0.035$) 3. Associated with LN metastasis ($p = 0.005$)	[37]

Abbreviations: CCRT, concurrent chemoradiotherapy; HR, hazard ratio; OS, overall survival; CEA, carcinoembryonic antigen; LN, lymph node; C/T, chemotherapy; *GALNT14*, N-acetylgalactosaminyltransferase14

4. GALNT14 enzyme level is associated with GALNT14 SNP genotype

Current studies of the predictive role of *GALNT14*-rs9679162 SNP showed that in HCC and esophageal cancer ("carcinoma"), patients with the "TT" genotype had a better prognosis, whereas in other cancers ("adenocarcinoma"), patients with the "GG" genotype had a better outcome [19][22][27][29][33][35][37]. Since *GALNT14* enzyme levels have been associated with cancer characteristics, it can be speculated that *GALNT14* enzyme expression levels were associated with different SNP genotypes. This hypothesis has been examined in HCC [22] and PDA [35] tissues. The protein levels of *GALNT14* and cFLIP-S, an inhibitor of the apoptotic signal transduction, in relation to the *GALNT14* genotype were investigated in a cohort of 44 patients with surgical resection of HCC [22]. Analysis of quantitative protein levels on the genotype-stratified patient subgroups showed: (i) the cancer parts had higher *GALNT14* protein levels than those of the noncancer parts ($p = 0.008$ and < 0.001 for "TT" and "non-TT" genotypes, respectively); and (ii) a significantly higher cancer to noncancer (C/non-C) ratio of *GALNT14* expression was noted in the "TT" genotype compared with the "non-TT" genotype ($p = 0.001$). Additionally, the C/non-C ratios of cFLIP-S were significantly lower in the "TT" genotype than those in the "non-TT" genotype ($p = 0.014$). Glycoproteomic analysis showed that the glycosylated residues of death receptor 5 (DR5) in the "TT" patients-derived HCC tissues were clustered in the two major glycosylation sites, in contrast to a scattered glycosylation pattern in the "non-TT" liver tumor tissues. These molecular findings suggested that the cancerous tissues from HCC patients with "TT" genotype were more sensitive to extrinsic apoptosis signaling compared with those with "non-TT" genotype.

In PDA, a preliminary assessment of the *GALNT14* enzyme expressions from 20 patients (10 with "TT" and 10 with "GG" genotype) was performed [35]. Among them, patients with "TT" genotype had higher expression levels of *GALNT14* while those with "GG" genotype exhibited lower *GALNT14* levels in the cancerous cells, albeit the pattern was reversed in the islet cells. This finding suggested that *GALNT14* protein in PDA had an oncogene-like function, similar to what was reported in breast and ovarian cancers [13][14].

5. GALNT14 enzyme levels were associated with aggressiveness of breast, ovarian cancer, NSCLC and neuroblastoma

5.1 Breast cancer

The association between cancer characteristics and *GALNT14* protein expression has been studied in breast cancer [38]. The *GALNT14* was over-expressed in most breast cancer tissues (47/56, 83.9%), but in only 7/48 (14.6%) non-malignant breast tissues. Higher histological grade of invasive ductal carcinoma was correspondent to lower expression level of *GALNT14*. Moreover, Song *et al.* reported that *GALNT14* expression in breast cancer was linked to lung metastasis [13]. High expression of *GALNT14* in advanced breast cancer was associated with shorter lung metastasis-free survival ($p = 0.0015$). *GALNT14* promotes breast cancer metastasis to lung by enhancing the initiation of metastatic colonies and their subsequent growth into overt metastases. The inhibitory effect of lung-derived bone morphogenetic proteins (BMPs) on cancer self-renewal was overcome by *GALNT14*, which facilitated metastasis initiation within the lung microenvironment. In addition, *GALNT14* not only enhanced the recruitment of macrophages to the site of metastases, but also exploited

macrophage-derived fibroblast growth factors (FGFs). Moreover, the KRAS-PI3K-c-JUN signaling was identified as an upstream pathway that accounted for the elevated expression of GALNT14 in lung-metastatic breast cancer. In a study conducted with MCF-7 breast cancer cell line, overexpression of GALNT14 significantly enhanced cell proliferation, migration and tumor invasion, while knockdown of GALNT14 reduced clonogenicity and attenuated cell migration and cell invasion [12]. Moreover, GALNT14 mediated O-glycosylation of EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2) which significantly increased the invasion ability of breast cancer cell lines (MCF-7 and MBA-MD-231) [39]. The chemosensitivity of breast cancer was also associated with GALNT14. Osterix decreased the chemosensitivity and enhanced the anti-apoptosis by upregulating *GALNT14* [40]. Further analysis of 129 breast cancer patients showed that high expression of GALNT14 in breast cancer tissues was associated with higher HER2 (76.7% vs. 58.1%, $p = 0.038$), higher clinical stages ($p < 0.0001$) and shorter DFS ($p = 0.029$). Another study showed that *GALNT14* regulated the stability of P-gp, the efflux pump localized on the cell membrane, which further promoted multidrug resistance [16]. These studies suggested GALNT14 might play an important role in modulating breast cancer aggressiveness and could be considered as a therapeutic target for treatment.

5.2 Ovarian cancer

Overexpression of GALNT14 was found in ovarian cancer [14][41]. Knockdown of *GALNT14* significantly suppressed cell migration and cellular morphology change through aberrant glycosylation of transmembrane mucin 13 [14]. Yang *et al.* demonstrated that the expression levels of miR-125a were downregulated and negatively related to GALNT14 expression in ovarian cancer tissues [42]. Moreover, luciferase reporter assay identified *GALNT14* as a direct target of miR-125a, and overexpression of miR-125a markedly reduced the expression of GALNT14. Both miR-125a mimics and *GALNT14* siRNA suppressed the activity of matrix metalloproteinase (MMP)-2 and MMP-9, further inhibited the extracellular matrix degradation. A recent study showed that aberrant expression of BORIS (Brother of the Regulator of Imprinted Sites) altered cell migration and invasion via upregulation of *GALNT14*, suggesting BORIS as a potential therapeutic target in ovarian high-grade serous carcinoma [43].

5.3 NSCLC

The expression of GALNT14 was highly associated with shorter RFS in a clinicogenomics study including 138 NSCLC patients [44]. In PDA, melanoma and NSCLC cell lines, GALNT14 expression was correlated with Apo2L/TRAIL sensitivity [11]. Overexpression of *GALNT14* increased cellular Apo2L/TRAIL sensitivity, whereas RNA interference of *GALNT14* expression reduced responsiveness. Through modulation of extracellular DR4 and DR5 O-glycosylation sites, GALNT14 enhanced apoptotic signaling. Immunohistochemistry assays that measured GALNT14 expression had been developed to select NSCLC patients who might be more sensitive to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist antibody) [45]. Moreover, GALNT14 increased the sensitivity of the WNT signaling and increased the stability of the β -catenin protein, leading to induced HOXB9 expression and acquisition of an invasive phenotype [15]. A meta-analysis of clinical genomics data showed that overexpression of GALNT14 or HOXB9 was strongly correlated with reduced RFS and increased HR, suggesting that targeting the GALNT14/WNT/HOXB9 axis might be a novel therapeutic approach to inhibit NSCLC metastasis.

5.4 Neuroblastoma

A *GALNT14* mutation (c.802C > T) was identified as a neuroblastoma predisposition gene and predicted as functionally damaging by the PolyPhen2 (Polymorphism Phenotyping v2) and SIFT (Sorting Intolerant From Tolerant) scoring methods [17]. Furthermore, high expression of GALNT14 was associated with a worse OS in a public dataset of 88 neuroblastoma samples. *GALNT14* is located closely to *ALK* on 2p23.1, a region previously discovered in linkage with neuroblastoma.

6. Conclusions

GALNT14, an initiating enzyme of O-glycosylation, has been demonstrated to play a pivotal role in cancer cell proliferation, migration and metastases. The expression level of *GALNT14* as well as its SNP genotype can be used to predict clinical outcomes in various types of cancer. However, the relationships between the *GALNT14* SNPs, the enzyme expressions, and the tumor behaviors have not been fully unveiled. Here, we summarized the current knowledge of GALNT14 in various cancers, particularly focusing on its role as a biomarker. Further studies are still needed to provide the missing mechanisms regarding the links between the genotypes and expression levels, as well as other GALNT14-involved microenvironmental elements, which can modulate cancer behaviors. Hopefully, with these knowledges, new therapeutic strategies can be devised in the future.

References

1. Moremen, K.W.; Tiemeyer, M.; Nairn, A.V. Vertebrate protein glycosylation: Diversity, synthesis and function. *Nat Rev Mol Cell Biol* 2012, 13, 448-462.
2. Tarp, M.A.; Clausen, H. Mucin-type o-glycosylation and its potential use in drug and vaccine development. *Biochim Biophys Acta* 2008, 1780, 546-563.
3. Tian, E.; Ten Hagen, K.G. Recent insights into the biological roles of mucin-type o-glycosylation. *Glycoconj J* 2009, 26, 325-334.
4. Tran, D.T.; Ten Hagen, K.G. Mucin-type o-glycosylation during development. *J Biol Chem* 2013, 288, 6921-6929.
5. Bennett, E.P.; Mandel, U.; Clausen, H.; Gerken, T.A.; Fritz, T.A.; Tabak, L.A. Control of mucin-type o-glycosylation: A classification of the polypeptide galnac-transferase gene family. *Glycobiology* 2012, 22, 736-756.
6. Ten Hagen, K.G.; Fritz, T.A.; Tabak, L.A. All in the family: The udp-galnac:Polypeptide n-acetylgalactosaminyltransferases. *Glycobiology* 2003, 13, 1R-16R.
7. Beaman, E.M.; Brooks, S.A. The extended ppgalnac-t family and their functional involvement in the metastatic cascade. *Histol Histopathol* 2014, 29, 293-304.
8. Wang, H.; Tachibana, K.; Zhang, Y.; Iwasaki, H.; Kameyama, A.; Cheng, L.; Guo, J.; Hiruma, T.; Togayachi, A.; Kudo, T., et al. Cloning and characterization of a novel udp-galnac:Polypeptide n-acetylgalactosaminyltransferase, pp-galnac-t14. *Biochem Biophys Res Commun* 2003, 300, 738-744.
9. Hagen, F.K.; Hazes, B.; Raffo, R.; deSa, D.; Tabak, L.A. Structure-function analysis of the udp-n-acetyl-d-galactosamine:Polypeptide n-acetylgalactosaminyltransferase. Essential residues lie in a predicted active site cleft resembling a lactose repressor fold. *J Biol Chem* 1999, 274, 6797-6803.
10. Unligil, U.M.; Zhou, S.; Yuwaraj, S.; Sarkar, M.; Schachter, H.; Rini, J.M. X-ray crystal structure of rabbit n-acetylglucosaminyltransferase i: Catalytic mechanism and a new protein superfamily. *EMBO J* 2000, 19, 5269-5280.
11. Wagner, K.W.; Punnoose, E.A.; Januario, T.; Lawrence, D.A.; Pitti, R.M.; Lancaster, K.; Lee, D.; von Goetz, M.; Yee, S.F.; Totpal, K., et al. Death-receptor o-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand apo2l/trail. *Nat Med* 2007, 13, 1070-1077.
12. Huanna, T.; Tao, Z.; Xiangfei, W.; Longfei, A.; Yuanyuan, X.; Jianhua, W.; Cuifang, Z.; Manjing, J.; Wenjing, C.; Shaochuan, Q., et al. Galnt14 mediates tumor invasion and migration in breast cancer cell mcf-7. *Mol Carcinog* 2015, 54, 1159-1171.
13. Song, K.H.; Park, M.S.; Nandu, T.S.; Gadad, S.; Kim, S.C.; Kim, M.Y. Galnt14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment. *Nat Commun* 2016, 7, 13796.
14. Wang, R.; Yu, C.; Zhao, D.; Wu, M.; Yang, Z. The mucin-type glycosylating enzyme polypeptide n-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. *Oncol Rep* 2013, 30, 667-676.
15. Kwon, O.S.; Oh, E.; Park, J.R.; Lee, J.S.; Bae, G.Y.; Koo, J.H.; Kim, H.; Choi, Y.L.; Choi, Y.S.; Kim, J., et al. Galnac-t14 promotes metastasis through wnt dependent hoXB9 expression in lung adenocarcinoma. *Oncotarget* 2015, 6, 41916-41928.
16. Shan, J.; Liu, Y.; Wang, Y.; Li, Y.; Yu, X.; Wu, C. Galnt14 involves the regulation of multidrug resistance in breast cancer cells. *Transl Oncol* 2018, 11, 786-793.
17. De Mariano, M.; Gallesio, R.; Chierici, M.; Furlanello, C.; Conte, M.; Garaventa, A.; Croce, M.; Ferrini, S.; Tonini, G.P.; Longo, L. Identification of galnt14 as a novel neuroblastoma predisposition gene. *Oncotarget* 2015, 6, 26335-26346.
18. Liang, K.H.; Lin, C.C.; Yeh, C.T. Galnt14 snp as a potential predictor of response to combination chemotherapy using 5-fu, mitoxantrone and cisplatin in advanced hcc. *Pharmacogenomics* 2011, 12, 1061-1073.
19. Yeh, C.T.; Liang, K.H.; Lin, C.C.; Chang, M.L.; Hsu, C.L.; Hung, C.F. A single nucleotide polymorphism on the galnt14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. *Int J Cancer* 2014, 134, 1214-1224.
20. Lin, W.R.; Hsu, C.W.; Chen, Y.C.; Chang, M.L.; Liang, K.H.; Huang, Y.H.; Yeh, C.T. Galnt14 genotype, alpha-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. *Mol Clin Oncol* 2014, 2, 630-640.
21. Liang, K.H.; Yang, P.C.; Yeh, C.T. Genotyping the galnt14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons. *Oncol Lett* 2014, 8, 2215-2220.

22. Liang, K.H.; Lin, C.L.; Chen, S.F.; Chiu, C.W.; Yang, P.C.; Chang, M.L.; Lin, C.C.; Sung, K.F.; Yeh, C.; Hung, C.F., et al. Galnt14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. *Pharmacogenomics* 2016, 17, 353-366.
23. Lin, W.R.; Hsu, C.W.; Yeh, C.S.; Chen, Y.C.; Chang, M.L.; Liang, K.H.; Lin, C.C.; Chu, Y.D.; Yeh, C.T. Combinations of single nucleotide polymorphisms wwox-rs13338697, galnt14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. *Asia Pac J Clin Oncol* 2018, 14, e54-e63.
24. Lin, C.C.; Hsu, C.W.; Chen, Y.C.; Chang, M.L.; Liang, K.H.; Lai, M.W.; Lin, C.L.; Chien, R.N.; Lin, K.H.; Yeh, C.T. A galnt14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: Systemic or hepatic arterial infusion chemotherapy. *Pharmacogenomics J* 2019.
25. Honing, J.; Smit, J.K.; Muijs, C.T.; Burgerhof, J.G.; de Groot, J.W.; Paardekooper, G.; Muller, K.; Woutersen, D.; Legdeur, M.J.; Fiets, W.E., et al. A comparison of carboplatin and paclitaxel with cisplatin and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. *Ann Oncol* 2014, 25, 638-643.
26. Stahl, M.; Budach, W.; Meyer, H.J.; Cervantes, A.; Group, E.G.W. Esophageal cancer: Clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010, 21 Suppl 5, v46-49.
27. Tsou, Y.K.; Liang, K.H.; Lin, W.R.; Chang, H.K.; Tseng, C.K.; Yeh, C.T. Galnt14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma. *Oncotarget* 2017, 8, 29151-29160.
28. Piessen, G.; Messager, M.; Leteurtre, E.; Jean-Pierre, T.; Mariette, C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. *Ann Surg* 2009, 250, 878-887.
29. Chen, T.H.; Lin, W.R.; Lee, C.; Chiu, C.T.; Hsu, J.T.; Yeh, T.S.; Lin, K.H.; Le, P.H.; Yeh, C.T. Prognostic stratification of advanced gastric signet ring cell carcinoma by clinicopathological factors and galnt14 genotype. *J Cancer* 2018, 9, 3540-3547.
30. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004, 350, 2343-2351.
31. Kuebler, J.P.; Wieand, H.S.; O'Connell, M.J.; Smith, R.E.; Colangelo, L.H.; Yothers, G.; Petrelli, N.J.; Findlay, M.P.; Seay, T.E.; Atkins, J.N., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage ii and iii colon cancer: Results from nsabp c-07. *J Clin Oncol* 2007, 25, 2198-2204.
32. Sanoff, H.K.; Carpenter, W.R.; Martin, C.F.; Sargent, D.J.; Meyerhardt, J.A.; Sturmer, T.; Fine, J.P.; Weeks, J.; Niland, J.; Kahn, K.L., et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage iii colon cancer. *J Natl Cancer Inst* 2012, 104, 211-227.
33. Lin, W.R.; Chiang, J.M.; Liang, K.H.; Lim, S.N.; Lai, M.W.; Tsou, Y.K.; Hsieh, T.Y.; Hsu, C.K.; Yeh, C.T. Galnt14 genotype predicts postoperative outcome of stage iii colorectal cancer with oxaliplatin as adjuvant chemotherapy. *Medicine (Baltimore)* 2016, 95, e3487.
34. Hasan, S.; Jacob, R.; Manne, U.; Paluri, R. Advances in pancreatic cancer biomarkers. *Oncol Rev* 2019, 13, 410.
35. Chiang, C.C.; Yeh, C.T.; Hwang, T.L.; Chu, Y.D.; Lim, S.N.; Chen, C.W.; Kuo, C.J.; Le, P.H.; Chen, T.H.; Lin, W.R. The galnt14 genotype predicts postoperative outcome of pancreatic ductal adenocarcinoma. *J Clin Med* 2019, 8.
36. Blechacz, B.; Gores, G.J. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. *Hepatology* 2008, 48, 308-321.
37. Liang, K.H.; Yeh, T.S.; Wu, R.C.; Yeh, C.N.; Yeh, C.T. Galnt14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma. *Oncol Lett* 2017, 13, 4215-4223.
38. Wu, C.; Guo, X.; Wang, W.; Wang, Y.; Shan, Y.; Zhang, B.; Song, W.; Ma, S.; Ge, J.; Deng, H., et al. N-acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. *BMC Cancer* 2010, 10, 123.
39. Zuo, T.; Shan, J.; Liu, Y.; Xie, R.; Yu, X.; Wu, C. Efemp2 mediates galnt14-dependent breast cancer cell invasion. *Transl Oncol* 2018, 11, 346-352.
40. Wu, J.; Chen, X.; Bao, Q.; Duan, R.; Jin, Y.; Shui, Y.; Yao, B.; Lu, X.; Wang, Y.; Cui, H., et al. Osterix decreases the chemosensitivity of breast cancer cells by upregulating galnt14. *Cell Physiol Biochem* 2017, 44, 998-1010.
41. Sheta, R.; Bachvarova, M.; Plante, M.; Gregoire, J.; Renaud, M.C.; Sebastianelli, A.; Popa, I.; Bachvarov, D. Altered expression of different galnactransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. *Int J Oncol* 2017, 51, 1887-1897.

42. Yang, J.; Li, G.; Zhang, K. Mir-125a regulates ovarian cancer proliferation and invasion by repressing galnt14 expression. *Biomed Pharmacother* 2016, 80, 381-387.
 43. Hillman, J.C.; Pugacheva, E.M.; Barger, C.J.; Sribenja, S.; Rosario, S.; Albahrani, M.; Truskinovsky, A.M.; Stablewski, A.; Liu, S.; Loukinov, D.I., et al. Boris expression in ovarian cancer precursor cells alters the ctcf cistrome and enhances invasiveness through galnt14. *Mol Cancer Res* 2019, 17, 2051-2062.
 44. Lee, E.S.; Son, D.S.; Kim, S.H.; Lee, J.; Jo, J.; Han, J.; Kim, H.; Lee, H.J.; Choi, H.Y.; Jung, Y., et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. *Clin Cancer Res* 2008, 14, 7397-7404.
 45. Stern, H.M.; Padilla, M.; Wagner, K.; Amler, L.; Ashkenazi, A. Development of immunohistochemistry assays to assess galnt14 and fut3/6 in clinical trials of dulanermin and drozitumab. *Clin Cancer Res* 2010, 16, 1587-1596.
-

Retrieved from <https://encyclopedia.pub/entry/history/show/7877>